Cargando…
NO/cGMP/pCREB re-activation reverses cognition deficits and attenuates amyloid-β neuropathology in transgenic models of Alzheimer’s disease
Autores principales: | Thatcher, Gregory RJ, Luo, Jia, VandeVrede, Lawren, Qin, Zhihui, Lee, Sue, Abdelhamid, Ramy, Bennett, Brian M, Jo LaDu, Mary, Tai, Leon, Larson, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765650/ http://dx.doi.org/10.1186/2050-6511-14-S1-P72 |
Ejemplares similares
-
Discovery of neuroprotective soluble guanylate cyclase modulators (GCMs) aciting via NO/GC/cGMP/CREB pathway
por: Siklos, Marton I, et al.
Publicado: (2013) -
An NO Donor Approach to Neuroprotective and Procognitive Estrogen Therapy Overcomes Loss of NO Synthase Function and Potentially Thrombotic Risk
por: VandeVrede, Lawren, et al.
Publicado: (2013) -
Analysis of cGMP signalling with transgenic mice expressing FRET-based cGMP sensors
por: Wen, Lai, et al.
Publicado: (2013) -
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
por: Samudra, Niyatee, et al.
Publicado: (2023) -
A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer’s disease
por: Luo, Jia, et al.
Publicado: (2016)